Company Lightlake Therapeutics OTC Bulletin Board
Equities
US53224T1051
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
2023 | Indivior completes acquisition of Opiant Pharmaceuticals | AN |
2023 | Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ryan Preblick
DFI | Director of Finance/CFO | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,268,677 | 4,860,817 ( 92.26 %) | 0 | 92.26 % |
Company contact information
Opiant Pharmaceuticals, Inc.
10710 Midlothian Turnpike Suite 125
23235, Richmond
+
https://www.opiant.com![address Lightlake Therapeutics](https://cdn.zonebourse.com/static/address/5637165.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+21.69% | 127B | |
+24.33% | 117B | |
+26.03% | 27.67B | |
-18.59% | 20.33B | |
-15.17% | 16.79B | |
-16.27% | 15.63B | |
+13.03% | 14.84B | |
-47.10% | 14.65B | |
+58.34% | 14.43B |
- Stock Market
- Equities
- OPNT Stock
- Stock
- Company Lightlake Therapeutics